Pediatric Endocrinology Diabetes and Metabolism

Cechy kliniczne odróżniające pediatryczną autoimmunologiczną chorobę Addisona i zespoły poliendokrynne: wnioski z 15 lat doświadczeń w Bagdadzie, Irak

Muneera Fadhil Ridha 1
,
Bayar Abdullah Ahmed 2
,
Wassan Nori 3

  1. Department of Paediatrics, Paediatric Endocrinology, College of Medicine, University of Baghdad, Iraq

  2. Hawler Directorate of Health, Erbil, Iraq

  3. Department of Obstetrics and Gynaecology, College of Medicine, Mustansiriyah University, Baghdad, Iraq

Pediatr Endocrinol Diabetes Metab 2026; 32 (2):

DOI: https://doi.org/10.5114/pedm.2026.162372
Data publikacji online: 2026/06/25
Plik artykułu
0428_Distinguishing clinical.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet 2014; 383: 2152–2167. doi: 10.1016/S0140-6736(13)61684-0.
  2. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyglandular syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002; 23: 327–364. doi: 10.1210/edrv.23.3.0466.
  3. Husebye ES, Allolio B, Arlt W, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med 2014; 275: 104–115. doi: 10.1111/joim.12162.
  4. Rushworth RL, Torpy DJ, Falhammar H. Adrenal crisis. N Engl J Med 2019; 381: 852–861. doi: 10.1056/NEJMra1807486.
  5. Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322: 1829–1836. doi: 10.1056/NEJM199006283222601.
  6. Nagamine K, Peterson P, Scott HS, et al. Positional cloning of the APECED gene. Nat Genet 1997; 17: 393–398. doi: 10.1038/ng1297-393.
  7. Neufeld M, Maclaren N, Blizzard RM. Autoimmune polyglandular syndromes. Pediatr Ann 1980; 9: 43–53. doi: 10.3928/0090-4481-19800401-07.
  8. Jimenez S, Crossen S. Missed diagnosis of Addison’s disease in adolescent presenting with fatigue. Agency for Healthcare Research and Quality (AHRQ) 2023. Available at: https://psnet.ahrq.gov/web-mm/missed-diagnosis-addisons-disease-adolescent-presenting-fatigue (accessed 25 Oct 2025).
  9. Capalbo D, Esposito A, Gaeta V, et al. The multiple faces of autoimmune Addison’s disease in children. Front Endocrinol (Lausanne) 2024; 15: 1411774. doi: 10.3389/fendo.2024.1411774.
  10. Al-Jurayyan NA, Al-Herbish AS, Al-Nuaim AA, et al. Addison’s disease in children and adolescents: clinical features and autoimmune associations in Saudi Arabia. Acta Paediatr 1995; 84: 172–176.
  11. Shaikh S, Nagendra L, Shaikh S, Pappachan JM. Adrenal failure: an evidence-based diagnostic approach. Diagnostics (Basel) 2023; 13: 1812. doi: 10.3390/diagnostics13101812.
  12. Bjørklund G, Pivin M, Hangan T, et al. Autoimmune polyendocrine syndrome type 1: clinical manifestations, pathogenetic features, and management approach. Autoimmun Rev 2022; 21: 103135. doi: 10.1016/j.autrev.2022.103135.
  13. Dineen R, Thompson CJ, Sherlock M. Adrenal crisis: prevention and management in adult patients. Ther Adv Endocrinol Metab 2019; 10: 2042018819848218. doi: 10.1177/2042018819848218.
  14. Perniola R, Fierabracci A, Falorni A. Autoimmune Addison’s disease as part of the autoimmune polyglandular syndrome type 1: historical overview and current evidence. Front Immunol 2021; 12: 606860. doi: 10.3389/fimmu.2021.606860.
  15. Lalrehman U, Hamza HM, Malik MM, et al. Diverse clinical manifestations and management strategies in autoimmune polyglandular syndrome: a review of cases. Ann Med Surg (Lond) 2025; 87: 2774–2783. doi: 10.1097/MS9.0000000000003207.
  16. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 364–389. doi: 10.1210/jc.2015-1710.
  17. Robles DT, Fain PR, Gottlieb PA, Eisenbarth GS. The genetics of autoimmune polyendocrine syndrome type II. Endocrinol Metab Clin North Am 2002; 31: 353–368. doi: 10.1016/S0889-8529(01)00015-9.
  18. Cárdenas-Roldán J, Rojas-Villarraga A, Anaya JM. How do auto-immune diseases cluster in families? A systematic review and meta-analysis. BMC Med 2013; 11: 73. doi: 10.1186/1741-7015-11-73.
  19. Tong CV, Ooi XY. Addison’s disease presenting with hyperpigmentation. BMJ Case Rep 2021; 14: e245610. doi: 10.1136/bcr-2021-245610.
  20. Mulligan TM, Sowers JR. Hyperpigmentation, vitiligo, and Addison’s disease. Cutis 1985; 36: 317–318, 322.
  21. Lee YY, Cho NH, Lee JW, et al. Clinical characteristics of patients with adrenal insufficiency in a general hospital. Endocrinol Metab 2017; 32: 83–89. doi: 10.3803/EnM.2017.32.1.83.
  22. Zou X, Fan Z, Zhao L, et al. Gastrointestinal symptoms as the first manifestation of antiphospholipid syndrome. BMC Gastroenterol 2021; 21: 148. doi: 10.1186/s12876-021-01736-2.
  23. Ach T, Hadami BY, Ghariani N, et al. Gastrointestinal manifestations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patient: major effect on treatment and prognosis. Endocrinol Diabetes Metab Case Rep 2023; 2023: 22-0352. doi: 10.1530/EDM-22-0352.
  24. Harvey TC. Addison’s disease and the regulation of potassium: the role of insulin and aldosterone. Med Hypotheses 2007; 69: 1120–1126. doi: 10.1016/j.mehy.2007.03.021.
  25. Smans LC, Zelissen PM. Does recovery of adrenal function occur in patients with autoimmune Addison’s disease? Clin Endocrinol (Oxf) 2011; 74: 434–437. doi: 10.1111/j.1365-2265.2010.03944.x.
  26. Baxter M, Gorick S, Swords FM. Recovery of adrenal function in a patient with confirmed Addison’s disease. Endocrinol Diabetes Metab Case Rep 2013; 2013: 130070. doi: 10.1530/EDM-13-0070.
  27. Pearce SHS, Gan EH, Napier C. Management of endocrine disease: residual adrenal function in Addison’s disease. Eur J Endocrinol 2021; 184: R61–R67. doi: 10.1530/EJE-20-0894.
  28. Gan EH, MacArthur K, Mitchell AL, et al. Residual adrenal function in autoimmune Addison’s disease: improvement after tetracosactide (ACTH1–24) treatment. J Clin Endocrinol Metab 2014; 99: 111–118. doi: 10.1210/jc.2013-2449.
  29. Obermayer-Straub P, Manns MP. Autoimmune polyglandular syndromes. Baillieres Clin Gastroenterol 1998; 12: 293–315. doi: 10.1016/s0950-3528(98)90136-1.
  30. Napier C, Gan EH, Mitchell AL, et al. Residual adrenal function in autoimmune Addison’s disease – effect of dual therapy with rituximab and depot tetracosactide. J Clin Endocrinol Metab 2020; 105: e1250–e1259. doi: 10.1210/clinem/dgz287.
  31. Bleicken B, Hahner S, Ventz M, Quinkler M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci 2010; 339: 525–531. doi: 10.1097/MAJ.0b013e3181db6b7a.
  32. Meyer G, Badenhoop K, Linder R. Increased prevalence of Addison’s disease in type 1 diabetes: German health insurance data 2010–2013. Clin Endocrinol (Oxf) 2016; 85: 860–866. doi: 10.1111/cen.13043.
  33. Freeland ZK, Lueking R, Tsai-Nguyen G, et al. Adrenal crisis and autoimmune polyglandular syndromes. Proc (Bayl Univ Med Cent) 2017; 30: 427–428. doi: 10.1080/08998280.2017.11930214.
  34. Clemente Hernández B, Muelas Rives I, Gracia Cazaña T, et al. Comorbidities associated with vitiligo: results from the EpiChron cohort. J Clin Med 2025; 14: 432. doi: 10.3390/jcm14020432.
  35. Xue SL, Feng Y, Shi T, et al. Autoimmune polyglandular syndrome among Chinese celiac disease patients: a survey of 243 individuals in China. Front Immunol 2025; 16: 1606237. doi: 10.3389/fimmu.2025.1606237.
  36. Nori W, Akram NN, Al-Kaabi MM. Probiotics in women and pediatrics health: a narrative review. Al-Anbar Med J 2023; 19: 10-16. doi: 10.33091/amj.2023.138442.1021.
ZGŁASZANIE PRAC
Udostępnij
without publication fees
Zintergrowane z
integrated with publons
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications